<Header>
<FileStats>
    <FileName>20161207_10-K-A_edgar_data_1173281_0001387131-16-008387_1.txt</FileName>
    <GrossFileSize>38120</GrossFileSize>
    <NetFileSize>8453</NetFileSize>
    <ASCII_Embedded_Chars>0</ASCII_Embedded_Chars>
    <HTML_Chars>24594</HTML_Chars>
    <XBRL_Chars>0</XBRL_Chars>
    <XML_Chars>0</XML_Chars>
    <N_Tables>4</N_Tables>
    <N_Exhibits>3</N_Exhibits>
</FileStats>
<SEC-Header>
0001387131-16-008387.hdr.sgml : 20161207
<ACCEPTANCE-DATETIME>20161207162523
ACCESSION NUMBER:		0001387131-16-008387
CONFORMED SUBMISSION TYPE:	10-K/A
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20150930
FILED AS OF DATE:		20161207
DATE AS OF CHANGE:		20161207

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ohr Pharmaceutical Inc
		CENTRAL INDEX KEY:			0001173281
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				465622433
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35963
		FILM NUMBER:		162039329

	BUSINESS ADDRESS:	
		STREET 1:		800 THIRD AVENUE
		STREET 2:		11TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
		BUSINESS PHONE:		(212) 682-8452

	MAIL ADDRESS:	
		STREET 1:		800 THIRD AVENUE
		STREET 2:		11TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BBM HOLDINGS, INC.
		DATE OF NAME CHANGE:	20070402

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRIME RESOURCE INC
		DATE OF NAME CHANGE:	20020513

</SEC-Header>
</Header>

 0001387131-16-008387.txt : 20161207

10-K/A
 1
 ohrp-10ka_093015.htm
 AMENDMENT TO FORM10-K

UNITED STATES   

   SECURITIES
AND EXCHANGE COMMISSION   

   WASHINGTON,
D.C. 20549   

FORM 10-K/A   

  (Amendment No. 1)  

 (Mark One) 

       ANNUAL
REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   

  For the fiscal year ended September
30, 2015  

           TRANSITION
REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   

  For the transition period from             
to.  

 Commission File No: 333-88480 

   OHR PHARMACEUTICAL,
INC.   

   (   Exac t
 Name of Regis t ran t
 as Specified in its Char t er)  

Delaware   
       
       46-5622433    
 
       (State or Other Jurisdiction of    
  Incorporation or Organization)   
       
       (I.R.S. Employer Identification No.)    

800 Third Ave, 11th Floor  
 New York, NY 10022  
 (Address of Principal Executive Offices)  

  212-682-8452  
 Registrant s telephone number, including area code  

 Securities registered under Section 12(b)
of the Exchange Act: Common Stock, par value $0.0001 per share 
Name of each exchange on which registered: NASDAQ Capital Market 
Securities registered under to Section 12(g) of the Exchange Act: None 

 Indicate by check mark if the registrant
is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes    
No     

 Indicate by check mark if the registrant
is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes    
No     

 Indicate by check mark whether the registrant:
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for past 90 days. Yes     No     

 Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted
and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this Chapter) during the preceding 12 months (or for such shorter
period that the registrant was required to submit and post such files). Yes    
No     

 Indicate by check mark if disclosure of
delinquent filers pursuant to Item 405 of Regulation S-K (  229.405) is not contained herein, and will not be contained, to
the best of registrant s knowledge, in definitive proxy or information statements incorporated by reference in Part III of
this Form 10-K or any amendment to this Form 10-K. Yes    
No     

 Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
of  large accelerated filer,   accelerated filer,  and  smaller reporting company  in Rule
12b-2 of the Exchange Act. 

 (Check One): Large accelerated filer    
Accelerated filer     Non-accelerated    
Smaller reporting company     

 Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Act). Yes    
No     

 The aggregate market value of the voting
and non-voting common equity held by non-affiliates at March 31, 2015, the last business day of the registrant s most recently
completed second fiscal quarter, was $65,938,100 (based on the closing price of the registrant s common stock on the NASDAQ
Capital Market on such date). Shares of common stock held by each executive officer and director and by each person who owns 10%
or more of the outstanding common stock of the registrant have been excluded in that such person might be deemed to be an affiliate.
This determination of affiliate status might not be conclusive for other purposes. 

 At December 1, 2016, the registrant had
32,076,396 shares of common stock outstanding. 

  DOCUMENTS INCORPORATED
BY REFERENCE  

 None. 

EXPLANATORY NOTE   

This Amendment No. 1 (this  Amendment )
to the Annual Report on Form 10-K for the fiscal year ended September 30, 2015 of Ohr Pharmaceutical, Inc., as filed with the Securities
and Exchange Commission on December 14, 2015 (the  Original Form 10-K ), is being filed for the sole purpose of filing
a revised consent of independent registered public accounting firm as Exhibit 23.1 

This Amendment speaks as of the original filing
date of the Original Form 10-K, does not reflect events that may have occurred subsequent to the original filing date and does
not modify or update in any way disclosures made in the Original Form 10-K. 

Part IV 

ITEM 15  
      EXHIBITS, FINANCIAL STATEMENT SCHEDULES   
 
 (a)(3) 

Exhibit 
Number   
       
       Description of Exhibit       
       
       The filings referenced   
  for incorporation by reference    
  are Ohr Pharmaceutical, Inc.    
  (File No.  001-35963 )        
 
      23.1  
       
       Consent of Independent Registered Public Accounting Firm   
       
      Filed herewith       

31.1  
       
       Section 302 Certification of Chief Executive Officer   
       
      Filed herewith   

32.2  
       
      Section 302 Certification of Chief Financial Officer  
       
      Filed herewith   

SIGNATURES  

Pursuant to the
requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.  

REGISTRANT:   

OHR PHARMACEUTICAL, INC.   

Dated:  December 7, 2016  
      By:  
       /s/    JASON SLAKTER    

Jason Slakter, CEO (Principal Executive Officer)   

Dated:  December 7, 2016  
      By:  
      /s/ SAM BACKENROTH   

Sam Backenroth, CFO   

(Principal Accounting and Financial Officer)   

Pursuant to the requirements
of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant
and in the capacities and on the dates indicated. 

*By:  
      /s/ Sam Backenroth  
      December 7, 2016   

Sam Backenroth  

Attorney-In-Fact  

<EX-23.1>
 2
 ex23-1.htm
 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Ohr Pharmaceutical, Inc. 10-K/A  

Exhibit 23.1  

Consent of Independent
Registered Public Accounting Firm  

Ohr Pharmaceutical, Inc. 

 New York, New York 

We hereby consent
to the incorporation by reference in the Registration Statement on Form S-3 (No. 333-201368) of Ohr Pharmaceutical, Inc.
of our report dated December 14, 2015, relating to the consolidated financial statements, and our report dated December 14, 2015
with respect to the effectiveness of internal control over financial reporting as of September 30, 2015, which reports appear in
this Annual Report on Form 10-K for the fiscal year ended September 30, 2015. 

/s/ MaloneBailey, LLP  

www.malone-bailey.com  

Houston, Texas  

December 7, 2016  

</EX-23.1>

<EX-31.1>
 3
 ex31-1.htm
 CERTIFICATION OF CHIEF EXECUTIVE OFFICER

Ohr Pharmaceutical, Inc. 10-K/A  

Exhibit 31.1  

Certification of Chief Executive Officer 
Pursuant to Section 302 of the 
Sarbanes-Oxley Act of 2002 

 I, Jason Slakter, certify that: 

1.  
      I have reviewed this report on Form 10-K of Ohr Pharmaceutical, Inc; and   

2.  
      Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.    

Dated: December
7, 2016 

/s/ Jason Slakter    

Jason Slakter  

Chief Executive Officer (Principal Executive Officer)  

</EX-31.1>

<EX-31.2>
 4
 ex31-2.htm
 CERTIFICATION OF CHIEF FINANCIAL OFFICER

Ohr Pharmaceutical, Inc. 10-K/A  

Exhibit 31.2  

Certification of Chief Financial Officer 
Pursuant to Section 302 of the 
Sarbanes-Oxley Act of 2002 

 I, Sam Backenroth,
certify that: 

1.  
      I have reviewed this report on Form 10-K of Ohr Pharmaceutical, Inc.; and    

2.  
      Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.   

Dated: December
7, 2016 

/s/     Sam Backenroth    

Sam Backenroth  

</EX-31.2>

